AIM: To determine whether endothelial progenitor cells (EPCs) can be used as delivery vehicle for adenoviral vectors and imaging probes for gene therapy in glioblastoma. METHODS: To use cord blood derived EPCs as delivery vehicle for adenoviral vectors and imaging probes for glioma gene therapy, a rat model of human glioma was made by implanting U251 cells orthotopically. EPCs were transfected with an adenovirus (AD5/carrying hNIS gene) and labeled with iron oxide and inoculated them directly into the tumor 14 d following implantation of U251 cells. Magnetic resonance imaging (MRI) was used to in vivo track the migration of EPCs in the tumor. The expression of gene products was determined by in vivo Tc-99m single photon emission computed tomography (SPECT). The findings were validated with immunohistochemistry (IHC). RESULTS: EPCs were successfully transfected with the adenoviral vectors carrying hNIS which was proved by significantly (P < 0.05) higher uptake of Tc-99m in transfected cells. Viability of EPCs following transfection and iron labeling was not altered. In vivo imaging showed the presence of iron positive cells and the expression of transgene (hNIS) product on MRI and SPECT, respectively, all over the tumors following administration of transfected and iron labeled EPCs in the tumors. IHC confirmed the distribution of EPC around the tumor away from the injection site and also showed transgene expression in the tumor. The results indicated the EPCs' ability to deliver adenoviral vectors into the glioma upon intratumor injection. CONCLUSION: EPCs can be used as vehicle to deliver adenoviral vector to glioma and also act as imaging probe at the same time.
AIM: To determine whether endothelial progenitor cells (EPCs) can be used as delivery vehicle for adenoviral vectors and imaging probes for gene therapy in glioblastoma. METHODS: To use cord blood derived EPCs as delivery vehicle for adenoviral vectors and imaging probes for glioma gene therapy, a rat model of humanglioma was made by implanting U251 cells orthotopically. EPCs were transfected with an adenovirus (AD5/carrying hNIS gene) and labeled with iron oxide and inoculated them directly into the tumor 14 d following implantation of U251 cells. Magnetic resonance imaging (MRI) was used to in vivo track the migration of EPCs in the tumor. The expression of gene products was determined by in vivo Tc-99m single photon emission computed tomography (SPECT). The findings were validated with immunohistochemistry (IHC). RESULTS: EPCs were successfully transfected with the adenoviral vectors carrying hNIS which was proved by significantly (P < 0.05) higher uptake of Tc-99m in transfected cells. Viability of EPCs following transfection and iron labeling was not altered. In vivo imaging showed the presence of iron positive cells and the expression of transgene (hNIS) product on MRI and SPECT, respectively, all over the tumors following administration of transfected and iron labeled EPCs in the tumors. IHC confirmed the distribution of EPC around the tumor away from the injection site and also showed transgene expression in the tumor. The results indicated the EPCs' ability to deliver adenoviral vectors into the glioma upon intratumor injection. CONCLUSION: EPCs can be used as vehicle to deliver adenoviral vector to glioma and also act as imaging probe at the same time.
Entities:
Keywords:
Adenovirus; Cord blood endothelial progenitor cells; Human sodium iodide symporter; Magnetic resonance imaging; Single photon emission computed tomography
Authors: Yunhui Liu; Moneeb Ehtesham; Ken Samoto; Christopher J Wheeler; Reid C Thompson; Luis P Villarreal; Keith L Black; John S Yu Journal: Cancer Gene Ther Date: 2002-01 Impact factor: 5.987
Authors: U Haberkorn; M Henze; A Altmann; S Jiang; I Morr; M Mahmut; P Peschke; W Kübler; J Debus; M Eisenhut Journal: J Nucl Med Date: 2001-02 Impact factor: 10.057
Authors: C M Kramm; M Sena-Esteves; F H Barnett; N G Rainov; D E Schuback; J S Yu; P A Pechan; W Paulus; E A Chiocca; X O Breakefield Journal: Brain Pathol Date: 1995-10 Impact factor: 6.508
Authors: Alice B Brown; Wendy Yang; Nils O Schmidt; Rona Carroll; Kim K Leishear; Nikolai G Rainov; Peter M Black; Xandra O Breakefield; Karen S Aboody Journal: Hum Gene Ther Date: 2003-12-10 Impact factor: 5.695
Authors: Maria-Adelaide Micci; Debbie R Boone; Margaret A Parsley; Jingna Wei; Igor Patrikeev; Massoud Motamedi; Helen L Hellmich Journal: Stem Cell Res Ther Date: 2015-07-21 Impact factor: 6.832
Authors: Anna Andrzejewska; Adam Nowakowski; Miroslaw Janowski; Jeff W M Bulte; Assaf A Gilad; Piotr Walczak; Barbara Lukomska Journal: Int J Nanomedicine Date: 2015-09-02